Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy aims to tackle Hard-to-Treat lymphoma

NCT ID NCT06252675

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times

Summary

This study tests whether combining two drugs—glofitamab and pirtobrutinib—can safely shrink tumors in adults with mantle cell lymphoma that returned or didn't respond to prior treatment. About 30 participants will receive the combination and be monitored for side effects and cancer response. The goal is to find a more effective option for this aggressive blood cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, Davis

    RECRUITING

    Davis, California, 95616, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • University of California, Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Email: •••••@•••••

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.